VIDEO: Phase 2 data for RGX-314 promising for neovascular AMD treatment

Issue: October 10, 2023

ByAshkan Abbey, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

SEATTLE — In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, FASRS, FAAO, overviews data evaluating subretinal delivery of RGX-314 gene therapy for the treatment of neovascular age-related macular degeneration.

The phase 2 study compared RGX-314 (Regenxbio/AbbVie) produced in a clinical research fashion with a manufacturing technique called Hyperstack and RGX-314 produced by a bioreactor commercial-based process. Both groups had a high-dose and low-dose arm.

“We can see that this could be an exciting option for our patients in the future in order to substantially reduce their treatment burden,” he said.

Published by:

Sources/Disclosures

Collapse

Source:

Abbey A. Subretinal delivery of RGX-314: Gene therapy for neovascular age-related macular degeneration (nAMD). Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.

Disclosures: Abbey reports receiving research support from Regenxbio.

American Society of Retina Specialists Meeting

Read more

VIDEO: Phase 2 data for RGX-314 promising for neovascular AMD treatment

Related Content